Literature DB >> 24186316

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.

Preetesh Jain1, Carlos Guillermo Romo, Hanna J Khoury, Hagop Kantarjian, Jorge Cortes.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; chronic phase; e1a2; ponatinib

Mesh：

Substances：

Year:  2013        PMID： 24186316      PMCID： PMC3815188          DOI： 10.3324/haematol.2013.092882

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

Authors:  Jorge Cortes; Alfonso Quintas-Cardama; Elias Jabbour; Susan O'Brien; Srdan Verstovsek; Gautam Borthakur; Farhad Ravandi; Guillermo Garcia-Manero; Elizabeth Burton; Jenny Shan; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08-10

2.  BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.

Authors:  Dan Jones; Rajyalakshmi Luthra; Jorge Cortes; Deborah Thomas; Susan O'Brien; Carlos Bueso-Ramos; Seema Hai; Farhad Ravandi; Marcos de Lima; Hagop Kantarjian; Jeffrey L Jorgensen
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?

Authors:  Stephen E Langabeer
Journal:  Med Oncol       Date:  2013-02-21       Impact factor: 3.064

Review 4.  BCR-ABL gene variants.

Authors:  J V Melo
Journal:  Baillieres Clin Haematol       Date:  1997-06

5.  Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Authors:  Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2009-06-16       Impact factor: 22.113

6.  Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Authors:  Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis J Giles; Weiqiang Zhao; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

Review 7.  Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL).

Authors:  Akimichi Ohsaka; Shigeo Shiina; Masaru Kobayashi; Hideyuki Kudo; Ryuji Kawaguchi
Journal:  Intern Med       Date:  2002-12       Impact factor: 1.271

8.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

9.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307
  9 in total
  1 in total

1.  Extramedullary blast crisis as initial presentation in chronic myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report.

Authors:  D I Ai; Wei Liu; Gary Lu; Keyur Pravinchandra Patel; Z I Chen
Journal:  Mol Clin Oncol       Date:  2015-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.